Enrolling By Invitation PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT05614531

Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1

A Multicenter, Nonrandomized, Open-label,Dose Escalation Clinical Trial to Assess the Safety and Efficacy of EXG001 307 After Intravenous Injection in Patients with Spinal Muscular Atrophy Type 1

Sponsor: Guangzhou Jiayin Biotech Ltd

Conditions Spinal Muscular Atrophy Type I

Interventions EXG001-307 injection

Updated 5 times since 2022 Last updated: Sep 6, 2024 Started: Feb 16, 2023 Primary completion: Aug 31, 2025 Completion: Aug 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Spinal Muscular Atrophy Type I, this trial is ongoing. The trial is conducted by Guangzhou Jiayin Biotech Ltd and has accumulated 5 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Feb 2026 — Present [monthly]

Enrolling By Invitation PHASE1/PHASE2
Oct 2024 — Feb 2026 [monthly]

Enrolling By Invitation PHASE1/PHASE2

Status: Recruiting → Enrolling By Invitation
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2022 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangzhou Jiayin Biotech Ltd

Data source: Guangzhou Jiayin Biotech Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China
• Shanghai, China